Skip to main content
Sirnaomics Ltd. logo

Sirnaomics Ltd. — Investor Relations & Filings

Ticker · 2257 LEI · 2549004JEEDTBC6EHW37 HKEX Professional, scientific and technical activities
Open in API
Filings indexed 402 across all filing types
Latest filing 2026-04-22 Share Issue/Capital Cha…
Country KY Cayman Islands
Listing HKEX 2257

About Sirnaomics Ltd.

http://www.sirnaomics.com

Sirnaomics Ltd. is a clinical-stage RNA therapeutics biopharmaceutical company focused on discovering and developing innovative drugs for indications with significant unmet medical needs. The company's pipeline addresses a broad spectrum of therapeutic areas, including oncology, fibrosis-related diseases, skin conditions, antiviral and cardiometabolic diseases, and medical aesthetics. Sirnaomics utilizes proprietary delivery platforms, which form the foundation of its RNA-based therapeutics. These platforms include the Polypeptide Nanoparticle (PNP) system for administering mRNA vaccines and therapeutics, and the GalNAc delivery platform for systemic administration of liver-targeting RNA interference (RNAi) therapeutics. The company is recognized as the first to achieve positive Phase IIb clinical outcomes in oncology using clinical-stage RNA therapeutics.

Recent filings

Filing Released Lang Actions
PROPOSED TERMINATION OF EXISTING SHARE OPTION SCHEME AND ADOPTION OF SHARE OPTION SCHEME
Share Issue/Capital Change Classification · 1% confidence The document is an official announcement by Sirnaomics Ltd.’s board proposing the termination of the existing share option scheme and adoption of a new 2026 Share Option Scheme. It outlines conditions for shareholder approval at an extraordinary general meeting and future issuance of shares under the option scheme. This relates to potential future share issuance and changes in the company’s capital structure rather than reporting of financial results or operational matters. Therefore, it falls under Share Issue/Capital Change (SHA).
2026-04-22 English
CHANGE OF COMPANY LOGO
Regulatory Filings Classification · 1% confidence The document is a Hong Kong Stock Exchange announcement (prefaced with the HKEX disclaimer) regarding a corporate identity change (company logo) for Sirnaomics Ltd. It is not a financial report, board/management change, dividend, or other specific category. It is a general regulatory announcement, thus best classified under Regulatory Filings (RNS).
2026-04-10 English
PROPOSED AMENDMENTS TO THE EXISTING MEMORANDUM AND ARTICLES OF ASSOCIATION AND ADOPTION OF THE NEW MEMORANDUM AND ARTICLES OF ASSOCIATION
Governance Information Classification · 1% confidence The document is a listing rule announcement regarding proposed amendments to the company’s Memorandum and Articles of Association (its constitutional governance documents), to be approved at the forthcoming AGM. It details governance rule changes and consolidation of the new articles. It is not the full AGM materials or proxy statement itself, but an announcement of governance amendments falling squarely under Governance Information.
2026-04-10 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2026
Regulatory Filings Classification · 1% confidence The document is the standard HKEX Form FF301 “Monthly Return for Equity Issuer and Hong Kong Depositary Receipts” which provides a detailed regulatory submission of movements in share capital, issued shares, options/RSUs and public float compliance. It is filed directly with the exchange under the Listing Rules, is neither an earnings release nor an annual/interim report nor a one-off fundraising announcement, but rather a recurring regulatory filing. It does not fit any more specific category, so it defaults to Regulatory Filings.
2026-04-08 English
VOLUNTARY ANNOUNCEMENT - INCREASE IN SHAREHOLDING IN THE COMPANY BY A DIRECTOR
Director's Dealing Classification · 1% confidence The document is a voluntary company announcement detailing the personal share purchase by Dr. Poon, a director of Sirnaomics Ltd., including the number of shares acquired, average price, and resulting shareholding percentage. This clearly matches the definition of a Director’s Dealing report (insider share transactions by a director).
2026-03-30 English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025
Earnings Release Classification · 1% confidence The document is titled “ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025” and provides audited consolidated annual results, key financial highlights, management discussion & analysis, and business highlights. It is the company’s initial public release of its full-year financial results rather than the full annual report itself. This aligns with an Earnings Release (ER), which is used for the initial announcement of periodical financial results. It is not merely a short notice nor is it a formal 10-K style report. FY 2025
2026-03-27 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.